PMID- 30864901
OWN - NLM
STAT- MEDLINE
DCOM- 20200313
LR  - 20211204
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 35
IP  - sup1
DP  - 2019 Mar
TI  - Sacubitril/valsartan can improve exercise performance in systolic chronic heart 
      failure patients: a case report.
PG  - 3-5
LID - 10.1080/03007995.2019.1576480 [doi]
AB  - OBJECTIVE: The cardiopulmonary exercise test (CPET) provides functional 
      prognostic parameters for patients with chronic heart failure (CHF), such as peak 
      volume of oxygen (VO(2)) and minute ventilation/carbon dioxide production 
      (VE/VCO(2)) slope. Sacubitril/valsartan (LCZ696) has been recently approved for 
      CHF patients as it reduces cardiovascular (CV) deaths and hospitalization for 
      heart failure (HF). However, the potential beneficial effects of this therapy on 
      exercise performance have been poorly investigated to date. CASE PRESENTATION: We 
      present a 64 year old woman with systolic HF (New York Heart Association [NYHA] 
      class III, ejection fraction 35%) due to moderate/severe aortic and tricuspid 
      regurgitation and pulmonary hypertension. The patient had several co-morbidities 
      and a history of CV surgery (mitral valve replacement due to bacterial 
      endocarditis). In November 2016, a CPET was performed in stable clinical 
      conditions, showing severe cardiogenic limitation with signs of pulmonary 
      hypertension (peak VO(2) 46% of predicted, VE/VCO(2) slope 36.5). According to 
      current guidelines, an angiotensin-converting enzyme inhibitor was replaced with 
      sacubitril/valsartan (24/26 mg for 2 weeks and then increased to 49/51 mg) 
      without any other change in medical therapy. At 2 months, CPET showed improvement 
      in exercise performance (peak VO(2) 61%, VE/VCO(2) slope 26.9). Echocardiographic 
      parameters also showed mild improvement, whereas renal function remained 
      unchanged. Thus, the dose of sacubitril/valsartan was increased to 97/103 mg. 
      CONCLUSIONS: We present a case of a systolic HF patient successfully treated with 
      sacubitril/valsartan who showed a rapid improvement of exercise performance at 
      CPET.
FAU - Mapelli, Massimo
AU  - Mapelli M
AD  - a Centro Cardiologico Monzino, IRCCS , Milan , Italy.
FAU - Vignati, Carlo
AU  - Vignati C
AD  - a Centro Cardiologico Monzino, IRCCS , Milan , Italy.
AD  - b Cardiovascular Section, Department of Clinical Sciences and Community Health , 
      University of Milan , Milan , Italy.
FAU - Paolillo, Stefania
AU  - Paolillo S
AD  - c IRCCS SDN , Naples , Italy.
FAU - De Martino, Fabiana
AU  - De Martino F
AD  - d Department of Advanced Biomedical Sciences, Section of Cardiology , Federico II 
      University of Naples , Naples , Italy.
FAU - Righini, Francesca
AU  - Righini F
AD  - a Centro Cardiologico Monzino, IRCCS , Milan , Italy.
FAU - Agostoni, Piergiuseppe
AU  - Agostoni P
AD  - a Centro Cardiologico Monzino, IRCCS , Milan , Italy.
AD  - b Cardiovascular Section, Department of Clinical Sciences and Community Health , 
      University of Milan , Milan , Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aminobutyrates/*therapeutic use
MH  - Angiotensin Receptor Antagonists/*therapeutic use
MH  - Biphenyl Compounds
MH  - Carbon Dioxide/metabolism
MH  - Chronic Disease
MH  - Drug Combinations
MH  - *Exercise
MH  - Exercise Test
MH  - Female
MH  - Heart Failure, Systolic/*drug therapy/physiopathology
MH  - Humans
MH  - Middle Aged
MH  - Tetrazoles/*therapeutic use
MH  - Valsartan
OTO - NOTNLM
OT  - Cardiopulmonary exercise test
OT  - chronic heart failure
OT  - sacubitril/valsartan
EDAT- 2019/03/14 06:00
MHDA- 2020/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2020/03/14 06:00 [medline]
AID - 10.1080/03007995.2019.1576480 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2019 Mar;35(sup1):3-5. doi: 10.1080/03007995.2019.1576480.